Navigation Links
Gene Study Offers Hope of Potent Anti-cancer Drugs

A study has opened the way for a new generation of drugs to combat the genes that give rise to the growth// of cancer tumors.

Scientists have carried out the widest survey yet of the genetic errors that causes tumors to grow. The findings will be used to design anti-cancer drugs targeted at counteracting mutations in a patient's DNA.

All cancers are thought to result from an accumulation of mutations in one or another of the 30,000 genes in the human genome. These mutations cause a cell to multiply uncontrollably to form a tumor that can then spread to other parts of the body.

Scientists have identified about 350 genes that have been implicated in the development of different cancers but, until now, have not had a clear idea about how many mutations in these genes were directly involved in triggering cancer.

The latest study analyzed 200 samples of cancerous tissue, surveying 500 genes and sequencing more than 250 million letters of the DNA code. An international team of more than 60 scientists led by Michael Stratton of the Wellcome Trust Sanger Institute in Cambridge identified 158 mutations in 120 genes that they believe can be implicated in cancer development.

Professor Stratton said the number of mutations that appear to be involved in driving the growth of cancerous tumors was larger than expected, but ultimately the technique will allow scientists to acquire a complete catalogue of all the mutations involved in each class of cancer.

"The human genome is a vast place and this, our first systematic exploration in cancer, has thrown up many surprises," said Professor Stratton. "We have found a much larger number of mutated driver genes produced by a wider range of forces than we expected. It's important because the more cancer genes we find, the more targets we'll have in terms of potential new drugs."

The study, published in the journal Nature, compared the genetic sequence of the DNA derived from a patient's tumor cells with the DNA of healthy cells from the same patient. The aim was to find the mutations that are present only in the tumor cells, and which could be implicated in their growth.

The scientists concentrated on a class of gene called the kinases, which are known to play a role in cancer. They identified about 1,000 mutations in these genes. The next stage was to try to assess whether these mutations were directly involved in "driving" cancer development, or whether they were harmless "passenger" mutations, which accumulate in the body with age.

Andrew Futreal, a senior team member at the Sanger, said some 158 driver mutations were identified in 120 of the kinase genes studied by the scientists.

"It turns out that most mutations in cancers are passengers. However, buried amongst them are much larger numbers of driver mutations than was previously anticipated," said Dr Futreal. "This suggests that many more genes contribute to cancer development than was thought.

"This study vindicates all of the effort that went into the Human Genome Project. Understanding the mutations that cause cancer is crucial in order to develop accurately targeted treatments," said Mark Walport, director of the Wellcome Trust.

Source-Bio-Bio Technology

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:

(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: